Labiotech.eu

News and Trends 23 Sep 2016

The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup

A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […]

September 23, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 22 Sep 2016

Evotec and Bayer renew their vows and take on Kidney Disease

Evotec and Bayer are approaching the 4th anniversary of a successful partnership in endometriosis treatments that made it to clinical trials just last month. To celebrate, they’re starting a new 5-year partnership, this time concerning kidney disease. Evotec has a long list of top-level partners, including Roche, Sanofi, Boehringer Ingelheim and Takeda. After the successful outcome of […]

September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Sep 2016

After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront

Earlier this week, we announced the launch of a new diagnostic tool for NASH by the French company Genfit. Now, Ireland strikes back with the acquisition of Akarna with a €44.8M upfront payment. Akarna focuses on the development of drugs for Non-Alcoholic Steato-Hepatitis (NASH) and boasts to count with a potentially best-in-class therapeutic candidate still in preclinical trials. The […]

September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Sep 2016

A new player has entered the Game: €29M for DDR Cancer Therapy

Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […]

September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 20 Sep 2016

This company just turned the lights ON for NanoMed Bioplastic

Bio-ON just patented the first application of bioplastic in nanomedicine with a diagnostic tool for cancer that will grant it access to a whole new market previously inaccessible to this industry. Italy-based Bio-ON is trying to change the world by producing alternative sustainable chemicals and bioplastic materials with industrial applications. Their newest product, minerv BIOMEDS, will be used […]

September 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports that its multiple sclerosis (MS) drug, siponimod, has reached its primary endpoint in Phase III […]

September 20, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 20 Sep 2016

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Genfit reinforced its leading place in the race to find a cure for NASH when it announced this morning the launch of a program to validate their new diagnostic tool. Genfit is already leading in the development of a cure for Non-Alcoholic Stato-Hepatitis (NASH) with its candidate, Elafibranor, which is in Phase III trials. Now, the French €600M biopharma has […]

September 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

This European Biotech Initiative wants to remediate Contaminated Land

It has been estimated that the impact of potentially polluting activities has affected around 3 million sites in Europe alone with great risk of adverse human health effects. As a result, there is considerable pressure to develop new innovative and cost-effective solutions to the problems posed by pollution. REMEDIATE ITN is making its approach. The project […]

September 20, 2016 - 5 minutesmins - By Joachim Eeckhout

News and Trends 19 Sep 2016

Italian Gene Therapy Biotech aims high by Collaborating with US Giant Amgen

Genenta Science and Amgen have teamed up to develop gene therapies for cancer. The Italian biotech from Milan raised €10M in series A funding last year and is already getting ready for clinical trials. Genenta is developing a gene therapy platform for haematopoietic stem cells and wants to bring it to the clinic. Together with the San Raffaele Hospital and Scientific […]

September 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Sep 2016

Novozymes moves on Microbes in recent Acquisition

The world’s leading producer of enzymes is making moves in the microbial world. Novozymes just acquired Organobalance, a German biotech specializing in microbes. Novozymes is a pillar of the Danish biotech scene and the world’s leading enzyme manufacturer. In 2000, it spun out of Novo Nordisk under the supervision of the World’s Best CEO, and […]

September 19, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 19 Sep 2016

Abingworth launches UK Immuno-Oncology Startup with Seed Funding

Just when we thought it couldn’t become any more intense, the field of immuno-oncology is heating up. VC giant Abingworth has seeded a new UK startup, GammaDelta Therapeutics, to bring its T cell therapy to the clinic. Abingworth, a huge British VC firm, has thrown its weight behind a new London-based immuno-oncology startup, GammaDelta Therapeutics. […]

September 19, 2016 - 3 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup

Evotec and Bayer renew their vows and take on Kidney Disease

After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront

A new player has entered the Game: €29M for DDR Cancer Therapy

German Biotech allies with Genentech in battle for Cancer Vaccine

This company just turned the lights ON for NanoMed Bioplastic

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

This European Biotech Initiative wants to remediate Contaminated Land

Italian Gene Therapy Biotech aims high by Collaborating with US Giant Amgen

Novozymes moves on Microbes in recent Acquisition

Abingworth launches UK Immuno-Oncology Startup with Seed Funding

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!